116 related articles for article (PubMed ID: 29296880)
1. CD86 regulates myeloma cell survival.
Gavile CM; Barwick BG; Newman S; Neri P; Nooka AK; Lonial S; Lee KP; Boise LH
Blood Adv; 2017 Nov; 1(25):2307-2319. PubMed ID: 29296880
[TBL] [Abstract][Full Text] [Related]
2. PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.
Moser-Katz T; Gavile CM; Barwick BG; Lee KP; Boise LH
Mol Cancer Res; 2022 Jul; 20(7):1122-1136. PubMed ID: 35380688
[TBL] [Abstract][Full Text] [Related]
3. CD28, a marker associated with tumoral expansion in multiple myeloma.
Robillard N; Jego G; Pellat-Deceunynck C; Pineau D; Puthier D; Mellerin MP; Barillé S; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Clin Cancer Res; 1998 Jun; 4(6):1521-6. PubMed ID: 9626472
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ
Elife; 2016 Jan; 5():. PubMed ID: 26731516
[TBL] [Abstract][Full Text] [Related]
6. Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma.
Huo J; Xu S; Lin B; Chng WJ; Lam KP
Leukemia; 2013 Apr; 27(5):1165-71. PubMed ID: 23138182
[TBL] [Abstract][Full Text] [Related]
7. [Costimulatory molecules in autoimmunity: role of CD28/CTLA4-CD80/CD86].
Nakajima A; Azuma M
Nihon Rinsho; 1997 Jun; 55(6):1419-24. PubMed ID: 9200926
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Morelli E; Leone E; Cantafio ME; Di Martino MT; Amodio N; Biamonte L; Gullà A; Foresta U; Pitari MR; Botta C; Rossi M; Neri A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Leukemia; 2015 Nov; 29(11):2173-83. PubMed ID: 25987254
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
[TBL] [Abstract][Full Text] [Related]
10. [Notch signaling pathway and multiple myeloma].
Gan ZH; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1380-3. PubMed ID: 19840488
[TBL] [Abstract][Full Text] [Related]
11. [Function of B7/CD28 in anti-myeloma immunoreaction through activating T cells].
Guo L; Zhang X; Qiu Y
Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):235-8. PubMed ID: 11601210
[TBL] [Abstract][Full Text] [Related]
12. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
13. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.
Judge TA; Wu Z; Zheng XG; Sharpe AH; Sayegh MH; Turka LA
J Immunol; 1999 Feb; 162(4):1947-51. PubMed ID: 9973463
[TBL] [Abstract][Full Text] [Related]
14. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Younes H; Leleu X; Hatjiharissi E; Moreau AS; Hideshima T; Richardson P; Anderson KC; Ghobrial IM
Clin Cancer Res; 2007 Jul; 13(13):3771-5. PubMed ID: 17606706
[TBL] [Abstract][Full Text] [Related]
15. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C; Thangavadivel S; Biedermann R; Brunner A; Stoitzner P; Willenbacher E; Greil R; Jöhrer K
J Hematol Oncol; 2016 Nov; 9(1):116. PubMed ID: 27809856
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice.
Asai T; Choi BK; Kwon PM; Kim WY; Kim JD; Vinay DS; Gebhardt BM; Kwon BS
Immunology; 2007 Jul; 121(3):349-58. PubMed ID: 17376197
[TBL] [Abstract][Full Text] [Related]
17. Targeting the CD80/CD86 costimulatory pathway with CTLA4-Ig directs microglia toward a repair phenotype and promotes axonal outgrowth.
Louveau A; Nerrière-Daguin V; Vanhove B; Naveilhan P; Neunlist M; Nicot A; Boudin H
Glia; 2015 Dec; 63(12):2298-312. PubMed ID: 26212105
[TBL] [Abstract][Full Text] [Related]
18. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.
McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN
Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604
[TBL] [Abstract][Full Text] [Related]
19. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
20. CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice.
Mathur M; Herrmann K; Qin Y; Gulmen F; Li X; Krimins R; Weinstock J; Elliott D; Bluestone JA; Padrid P
Am J Respir Cell Mol Biol; 1999 Oct; 21(4):498-509. PubMed ID: 10502560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
